Anticholinergic Drugs: Muscarinic Blockade, Clinical Uses and Anticholinergic Burden

Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care.

Overview and terminology

Anticholinergic drugs inhibit acetylcholine signaling, but the term should be used precisely. Most medicines called ‘anticholinergics’ in clinical practice are muscarinic receptor antagonists; nicotinic ganglion blockers and neuromuscular blockers are mechanistically distinct groups. Muscarinic receptor blockade alters secretions, airway and urinary smooth muscle, ocular accommodation, heart rate and central cognition [1,2].

Receptor mechanisms and classification

Muscarinic receptors M1, M3 and M5 primarily couple to Gq/11, whereas M2 and M4 couple to Gi/o. Blocking M3 inhibits gland secretion and smooth-muscle contraction; M2 inhibition can raise sinus rate.

  • Tertiary amines: atropine, scopolamine, oxybutynin and benztropine are uncharged to varying degrees at physiologic pH and may enter the CNS; atropine and scopolamine are not quaternary ammonium drugs.
  • Quaternary ammonium agents: glycopyrrolate, ipratropium, tiotropium and trospium have limited CNS penetration.
  • Bladder drugs: solifenacin, darifenacin, tolterodine, fesoterodine and oxybutynin reduce detrusor overactivity.
  • Other indications: scopolamine prevents motion sickness, tropicamide produces diagnostic mydriasis, and benztropine may relieve selected drug-induced parkinsonian symptoms [1].

Therapeutic applications

Atropine treats clinically important symptomatic bradycardia under appropriate resuscitation protocols and muscarinic effects in organophosphate poisoning, alongside other antidotal and supportive therapy. Ipratropium and long-acting muscarinic antagonists relieve airflow obstruction in COPD and selected asthma contexts. Antimuscarinic bladder drugs are one option for overactive bladder; beta-3 agonists offer an alternative when anticholinergic burden is problematic. Glycopyrrolate can reduce secretions and prevent muscarinic effects of neostigmine used for neuromuscular-blockade reversal [1].

Pharmacokinetics and precautions

Physicochemical properties and elimination vary substantially: trospium has limited CNS penetration and depends on renal excretion; oxybutynin has more central anticholinergic effects. Antimuscarinics can cause dry mouth, constipation, urinary retention, blurred vision, tachycardia and impaired sweating. Narrow-angle glaucoma or urinary outflow obstruction require indication-specific caution; not every ocular circumstance is an absolute class-wide contraindication [1].

Older adults and anticholinergic burden

The 2023 AGS Beers Criteria identify many strong anticholinergic drugs as potentially inappropriate in older adults owing to confusion, constipation, falls, delirium and cumulative cognitive effects. Oxybutynin has particularly concerning cognitive data, although uncertainty remains across individual agents. Review total exposure from antihistamines, antidepressants, antipsychotics and urinary medicines before adding another antimuscarinic [2].

Toxicity and clinical conclusion

Anticholinergic poisoning can produce delirium, hyperthermia, dry flushed skin, mydriasis, urinary retention and tachycardia. Management prioritizes supportive/toxicology care; physostigmine may be considered by specialists in carefully selected cases with appropriate monitoring. Use the most receptor- and organ-selective therapy consistent with the clinical indication [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. American Geriatrics Society. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71:2052–2081. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12478568/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *